CureVac Joins GlaxoSmithKline to Make Next-Gen Covid Shot

Feb.03 — CureVac has joined forces with GlaxoSmithKline Plc to create a next-generation Covid mRNA shot that could help protect against multiple variants of the pathogen, and it’s extended a partnership with Bayer AG to allow the German pharma giant to produce CureVac’s vaccine.  CureVac CEO Franz-Werner Haas spoke on “Bloomberg Markets.”

Articles You May Like

Introducing StockTracker Master Class Volume 1